2012
HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population
Kunz PL, Mojtahed A, Fisher GA, Ford JM, Chang DT, Balise RR, Bangs CD, Cherry AM, Pai RK. HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population. Applied Immunohistochemistry & Molecular Morphology 2012, 20: 13-24. PMID: 21617522, PMCID: PMC6402787, DOI: 10.1097/pai.0b013e31821c821c.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overBreast NeoplasmsEsophageal NeoplasmsFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansImmunohistochemistryIn Situ Hybridization, FluorescenceIncidenceMaleMiddle AgedReceptor, ErbB-2Retrospective StudiesStomach NeoplasmsUnited StatesConceptsGastroesophageal junction cancerHER2-positive adenocarcinomaGastroesophageal junction carcinomaJunction cancerHER2 expressionHER2 statusClinical Oncology/CollegeHER2-positive gastricGastroesophageal junction adenocarcinomaGastric Cancer TrialIntestinal-type adenocarcinomaPrimary tumor siteMembranous staining patternHER2/CEP17 ratioPrimary gastric adenocarcinomaTissue microarray approachASCO/CAPHER2 gene amplificationHER2 protein expressionJunction adenocarcinomaDiffuse adenocarcinomaGastroesophageal junctionPatient survivalTherapeutic optionsIntestinal type
2010
Comparison of intensity‐modulated radiotherapy and 3‐dimensional conformal radiotherapy as adjuvant therapy for gastric cancer
Minn AY, Hsu A, La T, Kunz P, Fisher GA, Ford JM, Norton JA, Visser B, Goodman KA, Koong AC, Chang DT. Comparison of intensity‐modulated radiotherapy and 3‐dimensional conformal radiotherapy as adjuvant therapy for gastric cancer. Cancer 2010, 116: 3943-3952. PMID: 20564136, DOI: 10.1002/cncr.25246.Peer-Reviewed Original ResearchConceptsIntensity-modulated radiotherapyCRT groupGastric cancerConformal radiotherapyIMRT patientsAcute gastrointestinal toxicityMedian radiation doseMedian serum creatinineGastroesophageal junction cancerOverall survival rateConcurrent chemotherapyKidney V20Liver V30Median liverRecent creatinineAdjuvant chemoradiotherapyAdjuvant therapyGastrointestinal toxicityIMRT groupLocoregional failurePostoperative chemoradiotherapyJunction cancerRenal functionSerum creatinineTreatment breaks
2009
Adjuvant chemoradiotherapy with carboplatin and a fluoropyrimidine for resectable gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience
de Bruin M, Kunz P, Sharma V, Norton J, Bastidas J, Chang D, Koong A, Koong A, Balise R, Ford J, Fisher G. Adjuvant chemoradiotherapy with carboplatin and a fluoropyrimidine for resectable gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience. Journal Of Clinical Oncology 2009, 27: e15674-e15674. DOI: 10.1200/jco.2009.27.15_suppl.e15674.Peer-Reviewed Original ResearchStanford Cancer CenterGEJ cancerAdjuvant chemoradiotherapyRetrospective reviewCycles of carboplatinPercentage of patientsGastroesophageal junction cancerGastroesophageal junction adenocarcinomaStandard of careExternal beam radiotherapyInfusional 5FUModified regimenPo bidPositive gastricResectable gastricAdjuvant treatmentCurative intentCurative resectionGastrointestinal toxicityMean followStage IBStage IIIAStage IIIBJunction cancerOverall survivalCarboplatin and fluoropyrimidine-based treatment for metastatic gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience
Kunz P, de Bruin M, Balise R, Fisher G, Ford J. Carboplatin and fluoropyrimidine-based treatment for metastatic gastric and gastroesophageal junction cancer: A retrospective review of the Stanford experience. Journal Of Clinical Oncology 2009, 27: e15686-e15686. DOI: 10.1200/jco.2009.27.15_suppl.e15686.Peer-Reviewed Original ResearchStanford Cancer CenterGastroesophageal junction cancerMetastatic gastricJunction cancerRetrospective reviewPossible treatment-related deathSingle-institution retrospective reviewCarboplatin AUC 6Regimen of carboplatinCycles of chemotherapyMedian overall survivalTreatment-related deathsStandard chemotherapy regimenFourty-five patientsGastroesophageal junction adenocarcinomaFluoropyrimidine-based treatmentSignet ring featuresAUC 6Chemotherapy-naïvePo bidChemotherapy regimenOnly patientsOverall survivalJunction adenocarcinomaMedian age